Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD

LARKSPUR, Calif.--(BUSINESS WIRE)--Vitrisa Therapeutics, Inc., a Company focused on developing a suite of platform technologies optimized for ocular therapeutics and an associated pipeline of therapeutics in sight-threatening ocular diseases, today announced that it has entered into an option agreement with Ohr Pharmaceutical for certain rights to the data from the MAKO study in wet-AMD (“wAMD”). Under the terms of the newly announced deal, Vitrisa will initially receive non-exclusive rights to

Full Story →